Cytek Biosciences Net Debt Growth & History (CTKB)
Cytek Biosciences's net debt was −$73.9M for fiscal 2025.
View full Cytek Biosciences company overviewCytek Biosciences annual net debt history
| Fiscal year | Period ended | Net debt | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$73.9M | $13.5M | — |
| 2024 | 2024-12-31 | −$87.4M | $68.0M | — |
| 2023 | 2023-12-31 | −$155.4M | $126.0M | — |
| 2022 | 2022-12-31 | −$281.4M | $83.3M | — |
| 2021 | 2021-12-31 | −$364.6M | — | — |
Cytek Biosciences quarterly net debt
| Fiscal quarter | Period ended | Net debt | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$57.1M | $965,000 | — |
| Q1 2026 | 2026-03-31 | −$49.3M | $35.0M | — |
| Q4 2025 | 2025-12-31 | −$73.9M | $13.5M | — |
| Q3 2025 | 2025-09-30 | −$76.7M | $74.3M | — |
| Q2 2025 | 2025-06-30 | −$58.0M | $109.3M | — |
| Q1 2025 | 2025-03-31 | −$84.3M | $73.5M | — |
| Q4 2024 | 2024-12-31 | −$87.4M | $68.0M | — |
| Q3 2024 | 2024-09-30 | −$151.0M | −$376,000 | — |
| Q2 2024 | 2024-06-30 | −$167.4M | −$49.6M | — |
| Q1 2024 | 2024-03-31 | −$157.8M | −$42.9M | — |
| Q4 2023 | 2023-12-31 | −$155.4M | $126.0M | — |
| Q3 2023 | 2023-09-30 | −$150.6M | $175.2M | — |
| Q2 2023 | 2023-06-30 | −$117.8M | $217.3M | — |
| Q1 2023 | 2023-03-31 | −$114.9M | $232.3M | — |
| Q4 2022 | 2022-12-31 | −$281.4M | $83.3M | — |
| Q3 2022 | 2022-09-30 | −$325.8M | — | — |
| Q2 2022 | 2022-06-30 | −$335.0M | — | — |
| Q1 2022 | 2022-03-31 | −$347.3M | — | — |
| Q4 2021 | 2021-12-31 | −$364.6M | — | — |
Cytek Biosciences net debt trends
Between the periods ended 2021-12-31 and 2025-12-31, Cytek Biosciences's net debt increased from −$364.6M to −$73.9M, a change of $290.7M. The latest reported quarter, Q2 2026, shows −$57.1M.
What net debt means
Net debt compares a company’s interest-bearing debt with its cash and cash equivalents. Positive net debt means debt exceeds cash, while a negative value indicates the company has more cash than debt on this measure.
How net debt is calculated
TickerStat calculates net debt as total interest-bearing debt minus cash and cash equivalents at the same reporting-period end. Short-term investments are not subtracted because they are not included in the standardized cash series. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Cytek Biosciences source filings ↗